Fast Market Research

Recently Released Market Study: Macular Degeneration - Pipeline Review, H2 2013

Fast Market Research recommends "Macular Degeneration - Pipeline Review, H2 2013" from Global Markets Direct, now available


Boston, MA -- (SBWIRE) -- 09/27/2013 -- Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Macular Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Macular Degeneration.
- A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Macular Degeneration pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Alcon, Inc., Genzyme Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bausch & Lomb Incorporated, Allergan, Inc., Shionogi & Co., Ltd., pSivida Corp., Advanced Cell Technology, Inc., GlaxoSmithKline plc, Genentech, Inc., Quark Pharmaceuticals, Inc., Lux Biosciences, Inc., Optherion, Inc., RetinaPharma Technologies, Inc., Novartis AG, Pfizer Inc., iCo Therapeutics Inc., Lpath, Inc., Mesoblast Ltd, BioDiem Ltd, ReGenX Biosciences, LLC, Circadian Technologies Limited, Ophthotech Corp., OXiGENE, Inc., Alexion Pharmaceuticals, Inc., Zenotech Laboratories Limited, Regeneron Pharmaceuticals, Inc., NeoStem, Inc., Hanall Pharmaceutical Co., Ltd., Sirion Therapeutics, Inc., Summit Corporation plc, ThromboGenics NV, PolyMedix, Inc., e-Therapeutics plc, NanoCarrier Co., Ltd., R-Tech Ueno, Ltd., Paloma Pharmaceuticals, Inc., Digna Biotech, S.L., Ceregene, Inc., Affitech A/S, Ora Bio Ltd., Foamix Ltd., Molecular Partners AG, Acucela Inc., Aciont Inc., Neovacs SA, Senju Pharmaceutical Co., Ltd., InCode BioPharmaceutics, Inc., OcuCure Therapeutics, Inc., Neurotech Pharmaceuticals, Inc., Gene Signal International SA., Promedior, Inc., Amalyte Pharmaceuticals, LLC, Iconic Therapeutics, Inc., Inotek Pharmaceuticals Corporation, Indus Biotech Private Limited, Cardax Pharmaceuticals, Inc., Intellect Neurosciences, Inc., Omeros Corporation, Angstrom Pharmaceuticals, Inc., FirstString Research, Inc., Stemedica Cell Technologies, Inc., Alimera Sciences, Inc., Biovista Inc., Sirnaomics, Inc., Resolvyx Pharmaceuticals, Inc, Charlesson LLC., MacuCLEAR, Inc., TRACON Pharmaceuticals, Inc., PanOptica, Inc., OHR Pharmaceutical Inc., Targa Therapeutics Corp., Pfenex Inc., SelectX Pharmaceuticals, Inc., Icon Bioscience, Inc., EyeGene, Inc., Varinel, Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Macular Degeneration - Pipeline Review, H1 2013
- Age Related Macular Degeneration - Pipeline Review, H1 2013
- Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2013
- Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2013
- Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2012
- Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2013
- Glaucoma - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013
- Asthma - Pipeline Review, H2 2013